Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer See more here
Read More
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway See more here
Read More
Melior Is Recognized as CRO of the Year by Life Sciences Review Life Sciences Review annually selects 10 preeminent CROs and has chosen Melior Discovery as the top CRO in 2023 The editors recognized Melior’s unique capabilities in the pre-clinical in vivo pharmacology space with its theraTRACE offering, its breadth…
Read More
SIRPant Immunotherapeutics (now BobcatBio) Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma See more here
Read More
Venatorx Pharmaceuticals Expands Senior Leadership Team Key Hires in CMC/Technical Operations, Business Development, and Finance See more here
Read More
iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease See more here
Read More
IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024 See more here
Read More
Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer See more here
Read More
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam No Clinical Safety or Efficacy Issues Identified No Requirement for Further Clinical Data or Trials See more here
Read More
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint Composite Efficacy Sustained at Late Follow-up Visit Safety Profile Consistent with Meropenem See more here
Read More